Akura: The Next-Generation for Venous Thromboembolism

About this Video

• Video Title: Akura: The Next-Generation for Venous Thromboembolism
• Channel: Mullings Group
• Speakers: Joe Mullings (Interviewer), Akura representative (Interviewee)
• Duration: 00:17:43

Introduction

This video features an interview at TCT 2024 discussing Akura, a new mechanical thrombectomy device for treating venous thromboembolism (VTE). The discussion focuses on Akura's differentiated features, clinical progress, and the advantages of being a Shifa Med company.

Key Takeaways

• Akura addresses unmet clinical needs in mechanical thrombectomy: It clears all clot types without clogging the catheter, reaches the target site effectively, and provides interoperative guidance.
• Akura's technological advantages: It uses aspiration and high-velocity jets to break up clots, features a low-profile steerable sheath, and offers continuous pressure monitoring and contrast injection capabilities.
• Clinical progress and FDA interactions: Akura has completed initial human trials with positive results and is expanding clinical trials in Brazil and the Dominican Republic. An IDE study for pulmonary embolism treatment is underway with the FDA.
• Remote procedure capabilities: Approximately 40% of Akura procedures this year were performed remotely via Zoom, highlighting the system's intuitive design and potential for wider accessibility.
• Benefits of being a Shifa Med company: Akura leverages Shifa Med's ecosystem for easier fundraising, streamlined back-office operations, shared resources (clinical sites, expertise), and collaborative opportunities.